DSIP
Delta Sleep Inducing Peptide / Delta Sleep-Inducing Peptide
DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated from the cerebral venous blood of rabbits during electrically induced slow-wave sleep by Swiss researchers Schoenenberger and Monnier in 1977. Despite its name, DSIP does not directly induce sleep but rather modulates sleep architecture, normalizes disturbed sleep-wake cycles, and influences stress adaptation, endocrine regulation, and pain perception. It is one of the earliest neuropeptides discovered and remains enigmatic due to its multiple peripheral and central effects that extend far beyond sleep regulation.
Mechanism of Action
Nonapeptide that modulates sleep architecture by increasing delta wave activity during slow-wave sleep. Acts through multiple mechanisms including GABA modulation, serotonergic signaling, and suppression of corticotropin-releasing hormone. Does not induce sedation but improves sleep quality.
Research Protocols
For research purposes only. Not medical advice.
Research protocols use 100-300mcg via subcutaneous or intramuscular injection 30-60 minutes before bedtime. Some protocols use 5-day cycles with 2-day breaks. Not recommended for continuous daily use.
Research Notes
Clinical Research Status
DSIP has been investigated in numerous clinical studies throughout the 1980s and 1990s, primarily in European research institutions, for insomnia, narcolepsy, chronic pain, opioid/alcohol withdrawal, and stress-related disorders. Despite promising results in several open-label and small controlled trials, no large Phase III trial has been conducted and DSIP holds no regulatory approval in any country. Research activity declined in the 2000s partly due to the peptide's instability and complex pharmacology that defied simple receptor-based drug development models. Interest has revived in recent years within the peptide therapy and biohacking communities.
Key Published Findings
A 1986 European Journal of Clinical Pharmacology study showed DSIP improved sleep onset latency and sleep efficiency in chronic insomniacs without morning hangover effects seen with benzodiazepines. Research demonstrated DSIP normalizes disrupted circadian cortisol patterns and reduces ACTH/cortisol responses to stress in both human and animal models. Clinical studies in opioid-dependent patients showed DSIP significantly reduced withdrawal symptoms and craving during detoxification. DSIP has been shown to modulate LH and GH secretion, lower blood pressure in hypertensive patients, and produce analgesic effects through met-enkephalin pathway modulation.
Safety Profile
Clinical studies consistently report DSIP is well-tolerated with no significant adverse effects at therapeutic doses (25-30 nmol/kg IV or 100 mcg SC). No tolerance, dependence, or withdrawal has been observed even with repeated administration over weeks. Unlike benzodiazepines and Z-drugs, DSIP does not impair cognitive function, suppress REM sleep, or produce respiratory depression. The primary practical concern is the peptide's instability in solution and susceptibility to enzymatic degradation, which affects dosing consistency rather than safety.
Drug Interactions & Contraindications
DSIP may potentiate the effects of other sedating compounds (benzodiazepines, opioids, antihistamines) through its modulatory effects on sleep architecture and endorphin systems. Its cortisol-modulating properties suggest caution in patients on corticosteroid therapy or with adrenal insufficiency. Patients on antihypertensive medications should monitor blood pressure as DSIP has demonstrated mild hypotensive effects in clinical studies. No absolute contraindications have been established, though use in pregnancy and severe hepatic/renal impairment is not recommended due to insufficient data.
Comparison to Related Compounds
Unlike benzodiazepines or Z-drugs (zolpidem, zopiclone), DSIP does not force sleep onset but rather normalizes the circadian regulation of sleep-wake cycles, improving natural sleep architecture. Compared to melatonin, DSIP has broader physiological effects beyond circadian rhythm signaling, including stress adaptation, pain modulation, and endocrine regulation. Relative to orexin receptor antagonists (suvorexant), DSIP represents a modulatory peptide approach rather than direct receptor blockade. Its multi-system effects distinguish it from all conventional sleep aids, suggesting it functions more as a homeostatic regulator than a targeted sedative-hypnotic.
Community Observations
Users typically dose DSIP at 100-300 mcg subcutaneously, administered 1-2 hours before desired sleep onset, often reporting improved sleep quality within 2-3 nights. The subjective experience is described as more restorative sleep with vivid dreams rather than sedation or forced drowsiness. Many users report best results with courses of 10-14 days rather than continuous use, noting that sleep improvements often persist after discontinuation. DSIP is frequently combined with other sleep-supporting peptides (Epithalon, GHRH analogs) and is popular among shift workers and those with travel-induced circadian disruption.
Half-Life
~15-25 minutes
Reconstitution
Bacteriostatic water (BAC)
Storage
Lyophilized
Refrigerate 2-8C up to 12 months.
Reconstituted
Refrigerate 2-8C. Use within 14 days.
US Legal Status
Also Known As
PeptideVault provides research-based summaries for informational purposes only. We do not host, distribute, or endorse vendor documentation. All certificates of analysis, GMP certificates, and vendor communications must be requested and verified directly by the buyer. Nothing on this platform constitutes legal, medical, or professional advice. Users are solely responsible for verifying vendor credentials and ensuring compliance with all applicable local, state, and federal laws before purchasing any research chemicals. Use of this platform constitutes acceptance of full personal responsibility.
Read full disclaimer